Clinical trials: Advanced Malignant Tumor
Solid Tumor, Adult, Brain Tumor, Primary
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
This is a first-in-human, open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
- Trial name
- NCT04901806
- Testing
- PBI-200
- Where
- 42 sites in United States, Australia and 9 more
- Volunteers
- 29 people
- Sponsor
- Pyramid Biosciences
Chordoma
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
This is a phase 2 clinical trial to determine whether the yeast-brachyury vaccine GI-6301 improves the effectiveness of radiation for patients with localized chordoma.
- Trial name
- NCT02383498
- Testing
- GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NantCell, Inc.
Solid Tumor
A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours
The treatment of cancer often involves the use of more than one drug at the same time. In this study, patients are treated with the already marketed drug paclitaxel (administered every 3 weeks by infusion)and with the…
- Trial name
- NCT00737555
- Testing
- CHR-2797
- Where
- 2 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- Chroma Therapeutics
Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment.
- Conditions
- Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma, Soft Tissue Sarcoma, Gastric/Esophageal Adenocarcinoma
- Trial name
- NCT00633789
- Testing
- brivanib
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 597 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with…
- Trial name
- NCT06625593
- Testing
- BG-C137, Anticancer Agents
- Where
- 52 sites in United States, Australia and 2 more
- Volunteers
- 168 people
- Sponsor
- BeOne Medicines
Solid Tumors
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT04774952
- Testing
- RMC-5552
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Revolution Medicines, Inc.
Advanced Solid Tumor, Recurrent Glioma
A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase (PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options.
- Trial name
- NCT04089449
- Testing
- PRT811
- Where
- 11 sites in United States
- Volunteers
- 86 people
- Sponsor
- Prelude Therapeutics Incorporated
Malignant Solid Tumors
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.
- Trial name
- NCT07268040
- Testing
- SHR-7787 Injection, SHR-1316 Injection, SHR-4849 Injection
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Solid Tumors, Non-Small Cell Lung Cancer
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other…
- Conditions
- Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- HS-20117 (NCT06621563)
- Testing
- HS-20117 combined HS-20093, HS-20117 combined Platinum-containing chemotherapy, HS-20117 combined HS-20093 and 5-FU
- Where
- China
- Volunteers
- 780 people
- Sponsor
- Hansoh BioMedical R&D Company
Advanced Solid Tumor
A Study of YL-17231 in Patients With Advanced Solid Tumors
This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of oral YL-17231 in patients with advanced solid tumors with KRAS mutation, so as to confirm the recommended phase 2 dose…
- Trial name
- NCT06078800
- Testing
- YL-17231
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Advanced Liver Cancer
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
This is an open-label phase 1 study with an escalation part and an expansion part.
- Trial name
- NCT04906434
- Testing
- ABSK-011
- Where
- 32 sites in United States, China and 1 more
- Volunteers
- 200 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Endometrial Cancer, Endometrial Cancer Recurrent
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab…
- Conditions
- Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer
- Trial name
- NCT02922764
- Testing
- RGX-104, Ipilimumab, Docetaxel
- Where
- 21 sites in United States
- Volunteers
- 146 people
- Sponsor
- Inspirna, Inc.
Cancer
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
- Trial name
- NCT04106492
- Testing
- SQ3370
- Where
- 10 sites in United States, Australia
- Volunteers
- 53 people
- Sponsor
- Shasqi, Inc.
Advanced Solid Tumor, Homologous Recombination Deficiency
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
- Conditions
- Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency
- Trial name
- NCT06525298
- Testing
- EIS-12656, Olaparib, Trastuzumab deruxtecan
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Eisbach Bio GmbH
Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
The goal of this clinical trial is to evaluate in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusion/rearrangement.
- Trial name
- NCT04353375
- Testing
- HMPL-453
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Hutchmed
Locally Advanced Solid Tumor, Metastatic Tumor
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
The goal of this clinical trial is to test the safety of TST003 in patients with cancer. The main question[s] it aims to answer are: What is the recommended dose patients can safely receive? How long does this drug remain in the…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
- Trial name
- NCT05731271
- Testing
- TST003
- Where
- 3 sites in United States
- Volunteers
- 111 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
Solid Tumor Malignancies
A Clinical Study of GO306 in Patients With Advanced Solid Tumors
This study employs a single-arm, open-label, non-randomized, dose-escalation design to investigate the safety, tolerability, and efficacy of GO306 Recombinant Oncolytic Vaccinia Virus Injection.
- Trial name
- NCT07128914
- Testing
- GO306
- Where
- 6 sites in China
- Volunteers
- 32 people
- Sponsor
- GeneSail Biotech (Shanghai) Co., Ltd.
Solid Tumor, C-Met Mutation-Related Tumors
Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161
Safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy evaluation of the selective c-MET inhibitor GST-HG161 in patients with advanced or metastatic solid tumors: An open, single and multiple…
- Trial name
- NCT04228406
- Testing
- GST-HG161
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Fujian Cosunter Pharmaceutical Co. Ltd
Advanced Malignancies, Metastatic Cancer
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability and assess preliminary efficacy of INCAGN01949 in subjects with advanced or metastatic solid tumors.
- Trial name
- NCT02923349
- Testing
- INCAGN01949
- Where
- 8 sites in United States, Spain and 2 more
- Volunteers
- 87 people
- Sponsor
- Incyte Biosciences International Sàrl